

Shareholder Q&A presentation

June 2023



The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the 'Presentation') have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ('FSMA'). Reliance upon the Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of the Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind.

The Presentation is being supplied to you solely for your information and does not propose to contain all information that may be required to evaluate ValiRx PLC ("the Company"). The Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

The Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract. Any investment in shares in the Company should only be made by you on the basis of information relating to the Company published through a regulatory news service, and your own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice as you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information contained in the Presentation or on its completeness, accuracy or fairness, nor is any responsibility accepted for any errors or misstatements in, or omission from, the Presentation or any direct or consequential loss however arising from any use of, or reliance on, the Presentation or otherwise in connection with it.

The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Canada, Japan, Australia, the Republic of South Africa or the Republic of Ireland or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Canada, Japan, Australia, the Republic of South Africa or the Republic of Ireland, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation is for distribution in the UK only to persons who: (a) fall within the exemptions contained in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (including certain investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts and other persons as specified therein); and (b) are "qualified investors" (within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) (as the same forms part of English law) ("Prospectus Regulation"), acting as principal or in circumstances to which section 86(2) of the Financial Services and Markets Act 2000 ("FSMA") applies, and (c) any other persons who may lawfully receive it. In addition, this Presentation is directed only at persons having professional experience in matters relating to investments and any investment or investment activity to which this Presentation relates is only available to such persons; persons who do not have professional experience in matters relating to investments should not rely or act on this Presentation.

The Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company. Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in the Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Company's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of the Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

No undertaking, representation, warranty or other assurance, expressed or implied, is made or given by or on behalf of the Company or any of its directors, officers, partners, employees or advisers or any other person as to the accuracy or the completeness of the information or opinions contained herein and to the extent permitted by law no responsibility or liability is accepted by any of them for any such information or opinions. Notwithstanding the aforesaid, nothing in this disclaimer shall limit or exclude liability for fraud.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that you have read and agree to comply with the contents of this disclaimer.

“ValiRx seeks to translate academic research effectively into clinical development for new drug candidates, focused on women’s health and cancer.”

“Ultimately, ValiRx seeks to unlock the vast potential of academic innovation.”



Evaluation projects ongoing – potential out-licensing candidates



Therapies undergoing out-licensing



Cytolytix

Single asset preclinical subsidiary for triple negative breast cancer



Focus on oncology and women's health

INAPHΛEA
— BIOLABS —

tCRO®

Specialist tCRO™ strategy, initiated with lab build



Highly experienced management team

Recent Achievements Overview

Clinical Assets out-licensing

VAL201 – TheoremRx LOI remains in place, with exclusivity carve-out from China

VAL201 – active marketing in China

VAL401 – external agency progressing commercial outreach



Building the tCRO®:

Lab leased and equipped

Strategic collaboration set up: Physiomics

Active advertising: Trade Events and Scientist.com

Active Business Development Team

Cytolytix Studies progressing

CLX001

Initial safety screen – no major concerns

Formulation optimisation – Lead and back up formulations generated and under study



New Staff hired in last 12 months:

Board:

Stella Panu

Senior Management:

Zai Ahmad, Cathy Tralau-Stewart, Andrew Carnegie

Inaphaea Team:

Melissa Barr, Dominic Lowen, Amelia Hatfield

Building Internal Pipeline


Barcelona – Master Agreement in place

KRAS(1); KRAS(2) – first Barcelona projects

VAL301 – further cell-based assays scheduled at Inaphaea



Building a Risk-diversified Preclinical Pipeline



Annual Ambition

Science Overview

- **Barcelona Evaluation Expanded to include KRAS-2**
- **VAL301 undergoing optimisation for evaluation**
- **Further Evaluation Agreements in advanced stages of negotiation**

- Seeking, reviewing and negotiating new pipeline assets, ensuring risk-diversification across stages of development, types of molecule and mechanisms of action
- Progressing current Evaluation projects
- Progressing current SPVs
- Ensuring all commercial opportunities have appropriate patent coverage
- Reviewing new technologies to bring into or collaborate with through Inaphaea
- Preparing and reviewing Inaphaea Science



Led by: Cathy Tralau-Stewart
Chief Scientific Officer

Scientific Support provided by:
Suzy, Zai and Scientific Advisory Board

Commercial Support provided by:
Mark, Andrew and Kevin

Logistics Support provided by:
Kumar

Project Scouting and Negotiation

- **Projects reviewed from global universities and charities**
- **6-8 projects reviewed in detail by Scientific Advisory Board each quarter**
- **Selected projects enter negotiations**
- **Aim for around 4 evaluations per year commenced**

- Seeking new pipeline assets by attending partnering events, scouring databases and building relationships with global Universities and Charities
- Co-ordinating the Scientific Advisory Board to receive information on new projects to review
- Negotiating with innovators to access new projects
- Communicating scientific progress to investors and industry representatives



Led by: Mark Treharne
Corporate Development Manager

Scientific Support provided by:
Cathy, Suzy, Zai and Scientific Advisory Board

Commercial Support provided by:
Suzy, Andrew and Kevin

- **CLX001 being developed for triple negative breast cancer and other cancers**
- **Nano-formulation optimisation identified lead formulations, now being tested**
- **Preclinical development plan under development**
- **Actively marketed to commercial partners for co-development or sub-licensing**

- Project Management of pre-clinical experiments, within Inaphaea and sourcing, contracting and managing sub-contracted research
- Interpreting data, drawing conclusions, planning experiments
- Preparation and submission of grant applications
- Reviewing, maintaining and preparing patent applications and patent office actions
- Preparing materials for Corporate Development presentations about Cytolytix
- Co-ordinating and updating all interested groups



Led by Zai Ahmad – Preclinical Project Manager

Scientific support provided by:
Cathy and Suzy

Additional scientific input from:
Martin Ulmschneider

Commercial Support provided by:
Suzy and Mark

Inaphaea Facility

- **Laboratory equipped for cell-based experiments**
- **Staff recruited and on-boarded to run facility**
- **Procedures set up to operate safely and in compliance with regulations**
- **Experimental validation assays underway**

- Ambition to offer experimental systems more closely related to human
- Ambition to demonstrate high reproducibility
- Leveraging ValiRx drug development expertise to support client projects
- Conducting cell-based assays on internal and external client projects
- Assessing new technologies and capabilities for use in the Inaphaea facility



Laboratory Team:

Melissa Barr, Dominic Lowen, Amelia Hatfield

Scientific and Management support provided by:

Zai

Scientific support provided by:

Cathy and Suzy


Commercial support provided by:

Andrew

Logistics and IT support provided by: Kumar

Services Business Development

- Collaborative agreement signed with Physiomics with further similar agreements under negotiation
- Proposals prepared and sent out for client review
- Conference Booth and materials created, events attended and positive feedback for service offering received
- Social media presence launched
- Registration accepted on CRO database: Scientist.com



Led by: Andrew Carnegie
Head of Strategic Commercial Development

Scientific Support provided by:
Cathy, Suzy and Zai

Commercial Support provided by:
Mark and Kevin

Social Media support provided by:
Kumar

- Raising awareness of Inaphaea at industry events
- Surveying client needs and recommending additions to the services provided
- Identifying client leads, initiating sales conversations, handling scientific queries, negotiating paperwork to initiate contracts
- Communicating with clients throughout projects
- Negotiating and project managing collaborations
- Maintaining accurate and timely social media accounts

Board and Corporate Governance

- **New NED hired in 2022 to enhance investor outreach**
- **Strategy reviewed and modified to account for current financial environment**

- Ensuring Board compliance with regulations
- Maintaining Company Policies and Procedures
- Co-ordinating with external Advisors, including Nomad and Brokers
- Monitoring the progress of the Executive Team against performance milestones
- Co-ordinating Human Resources activities
- Retaining a long term view of finances and commitments
- Partaking in shareholder communications and ensuring the shareholder interests are at the heart of the Company



Led by: Kevin Cox
Independent Non-Executive Chairman

Independent Non-Executives:
Stella and Martin

Executive Directors:
Suzy and Gerry

Public and Shareholder Relations



- **Inaphaea website and social media accounts launched**
- **ValiRx social accounts re-invigorated by engagement of V-formation**
- **ValiRx website optimised for SEO**

- Websites contain timely updates and good SEO
- Social Media activity to engage with investors, clients and collaborators to ensure public announcements are appropriately distributed
- Maintenance of email, phone and IT systems to ensure smooth communications
- Timely publication of all relevant commercial or scientific developments



Led by: Kumar Nawani
Head of Operations

Public Relations support provided by:
V-formation, Suzy and Kevin

Investor Relations support provided by:
Mark, Stella and Suzy

Science

Finance

Communications

Commercial

Pipeline

Development

Sales

Services

Evaluation

Revenues

Women's Health

Cancer



- Biobank of patient derived cells;
- Laboratory equipment;
- Intellectual Property;
- Trademarks, trade names and logos associated with Imagen;
- Data from Imagen's in-house screening programme



Provides more relevant cancer cell models for cell assay screening
Enables development of personalised cancer models
Broadens overall capability in Inaphaea
Access to wider market, including MedTech and BioPharma
Trading name recognised globally within the industry

- Suzanne Dilly – Chief Executive Officer
 - Suzanne.Dilly@valirx.com
- Cathy Tralau-Stewart – Chief Scientific Officer
 - Cathy.Tralau-Stewart@valirx.com
- Zai Ahmad – Preclinical Project Manager
 - Zai.Ahmad@valirx.com
- Kevin Cox – Non-Executive Chairman
 - Kevin.Cox@valirx.com
- Mark Treharne – Corporate Development Manager
 - Mark.Treharne@valirx.com
- Andrew Carnegie – Head of Strategic Commercial Development
 - Andrew.Carnegie@valirx.com

Valirx PLC (AIM:VAL)

Eliot Park Innovation Centre, 4 Barling Way, Nuneaton, CV10 7RH
Inaphaea BioLabs, MediCity, D6 Thane Road, Nottingham, NG90 6BH